←
Atherosclerosis3,272 posts
Atherosclerosis avatar

Atherosclerosis

@ATHjournal

Official account of #Atherosclerosis, the Journal of the European Atherosclerosis Society @society_eas 🫀

◷ Joined March 2019▧ 1,118 Photos and videos
LipidoSEEN avatar
⟳ Atherosclerosis retweeted
LipidoSEEN@LipidoSeen·Nov 15

📣Índice Triglicéridos glucemia combinado con la edad ✅Entre los 12 índices lipídicos evaluados, TyG especialmente en combinación con la edad demostró el mayor valor predictivo para el envejecimiento vascular en esta amplia población china @ATHjournal tinyurl.com/Itygedad

Post attachment
LipidoSEEN avatar
⟳ Atherosclerosis retweeted
LipidoSEEN@LipidoSeen·Nov 13

✅Screening hipercolesterolemia familiar mediante un perfil lipídico capilar es un método eficaz ❌50 % casos altamente sospechosos rechazaron seguimiento ➡️Punto corte deben adaptarse a la metodología y reevaluarse durante el cribado tinyurl.com/Cribadohf @ATHjournal

Post attachment
Pablo Corral MD avatar
⟳ Atherosclerosis retweeted
Pablo Corral MD@drpablocorral·Nov 13

👉 MUST READ; A landmark EAS Statement in the post-Lp(a)HORIZON era in @ATHjournal ☝️The European Atherosclerosis Society @society_eas delivers a timely, evidence-based message following the neutral results of Lp(a)HORIZON. 1️⃣ 78% Lp(a) reduction ≠ cardiovascular benefit. We must distinguish a causal risk factor from a validated therapeutic target. 2️⃣ Lp(a) remains a major cardiovascular risk factor. Measure it at least once in every adult. Family screening remains essential. 3️⃣ LDL-C lowering is our strongest actionable strategy. Intensive control of LDL-C and other risk factors can mitigate Lp(a)-associated risk. 4️⃣ Timing may be everything. Can a few years of treatment reverse decades of cumulative atherogenic exposure? 5️⃣ The science is far from over. Ongoing RCTs with different Lp(a)-lowering agents are essential. ☝️My key takeaway: A negative trial should change our assumptions, not replace scientific evidence with speculation. ☝️ Measure Lp(a). Lower LDL-C. Control global risk. Keep testing hypotheses with RCTs. 🔗 atherosclerosis-journal.com/… @BNordestgaard @ProfKausikRay @MeralKayikcoglu @KronenbergLab @j_rvl @SamiaMoraMD

Post attachment
LipidoSEEN avatar
⟳ Atherosclerosis retweeted
LipidoSEEN@LipidoSeen·Oct 19

📣A new era in atherothrombosis 👉Las nuevas terapias podrían transformar la enfermedad cardiovascular aterosclerótica, de ser afección propensa a la ruptura a enfermedad más crónica y controlada ➡️Revisión evidencias moleculares actuales @ATHjournal tinyurl.com/Molecularat

Post attachment
AMAREVA Riesgo Vascular avatar
⟳ Atherosclerosis retweeted
AMAREVA Riesgo Vascular@AMAREVA_Madrid·Sep 17

✅Los biomarcadores tradicionales suelen ser biológicamente asociativos en lugar de causales ✅Nuevos enfoques como la biología de sistemas, la medicina de redes y las imágenes moleculares están ampliando la atención cardiovascular de precisión tinyurl.com/Biomarca @ATHjournal

Post attachment
Pablo Corral MD avatar
⟳ Atherosclerosis retweeted
Pablo Corral MD@drpablocorral·Sep 16

👆Just published in @ATHjournal — from our #EAS 2026 Oral Presentation DOUBLE-HIT GENETIC DYSLIPIDEMIA: when two lifelong genetic drivers converge. 👉LDL-C 272 mg/dL 👉Lp(a) 766.4 nmol/L 👉apoB 198 mg/dL 🤔 Possible-to-probable familial hypercholesterolemia + extreme Lp(a) 👉The result: An extraordinary lifelong cumulative apoB burden, with diffuse coronary, carotid, subclavian, aortic and peripheral atherosclerosis — plus calcific aortic valve disease. 👆The message is simple: Atherosclerosis is about the magnitude × duration of exposure to apoB-containing particles. When FH and extreme Lp(a) coexist, the vascular system faces a true genetic “double hit.” With @alavallecobo & @natinardelli_ @society_eas #Atherosclerosis #LpA #FamilialHypercholesterolemia #ApoB #LDL #ASCVD #EAS2026

Post attachmentPost attachment
LipidoSEEN avatar
⟳ Atherosclerosis retweeted
LipidoSEEN@LipidoSeen·Sep 6

The interplay of genetics and modifiable risk in atherosclerosis ✅✅Interesante revisión Curiosamente, se observó que el tratamiento para reducir los lípidos era aún más beneficioso cuando la predisposición genética era fuerte

Post attachmentPost attachmentPost attachment
LipidoSEEN avatar
⟳ Atherosclerosis retweeted
LipidoSEEN@LipidoSeen·Sep 3

El alto riesgo inflamatorio afecta a aproximadamente ✅30 % de los pacientes con enfermedad cardiovascular aterosclerótica (ECVA) a nivel mundial ✅40 % de aquellos con enfermedad renal crónica concomitante 📣Estudio POSEIDON @ATHjournal tinyurl.com/POSEIDONStudy

Post attachment
LipidoSEEN avatar
⟳ Atherosclerosis retweeted
LipidoSEEN@LipidoSeen·Aug 26

Real-world variability and factors associated with individual low-density-lipoprotein cholesterol response to different doses of atorvastatin, rosuvastatin, and simvastatin @ATHjournal 👉👉Variabilidad efecto estatinas tinyurl.com/Varstatins

Post attachment
Pablo Corral MD avatar
⟳ Atherosclerosis retweeted
Pablo Corral MD@drpablocorral·Aug 26

I read Gonzalez et al. with great interest, especially alongside the newly published RISSCI-2 study in Atherosclerosis doi.org/10.1016/j.atheroscle… The observation of a median 53% LDL-C reduction with ezetimibe is certainly intriguing. But we should be very careful about what this study actually demonstrates. The 14 patients were retrospectively selected because they had already shown a marked LDL-C response to ezetimibe. They were not consecutive, there was no control group, and the prevalence of this response among unselected patients with ketogenic diet-associated hypercholesterolemia is unknown. Again the same problem! Therefore, 53% is not an estimate of the expected effect of ezetimibe in ketogenic hypercholesterolemia. It is the response observed in a selected group of hyperresponders. That distinction is fundamental. The mechanistic interpretation is even less certain. The authors propose increased dependence on intestinal cholesterol absorption, yet sterol-balance markers did not show a uniform hyperabsorption phenotype. Negative testing for monogenic FH or sitosterolemia does not establish that the LDL elevation was caused by the ketogenic diet, particularly when pre-diet lipid values were frequently unavailable and formal clinical FH criteria were not systematically applied. This becomes especially relevant in light of the new RISSCI-2 study in Atherosclerosis. In a prospective dietary intervention using stable-isotope tracing, differences in saturated-fat absorption did not explain interindividual LDL-C responsiveness, and changes in markers of cholesterol absorption and synthesis were remarkably similar between high and low responders. RISSCI-2 does not directly refute Gonzalez et al. The populations and hypotheses differ. But it provides an important reminder: A striking pharmacological response does not prove the mechanism responsible for the underlying hypercholesterolemia. Even more importantly, a retrospective case series of 14 selected responders cannot be used to ask why clinicians should prescribe statins or PCSK9-targeting therapies instead of a “$10 drug.” That comparison confuses hypothesis-generating evidence with randomized cardiovascular-outcomes evidence. Selecting patients because they had an exceptional response and subsequently presenting that exceptional response as evidence for treatment selection is not precision medicine; it is selection bias until prospectively validated. Ezetimibe is an excellent, inexpensive, evidence-based drug. That does not require inflating what this study demonstrates. The correct conclusion is actually the one contained in the paper itself: this is an interesting hypothesis-generating observation deserving prospective confirmation. Precision medicine starts with phenotype. But rigorous science starts with knowing what the study design allows us to claim.

Post attachment

11/ Read the peer-reviewed study: doi.org/10.1186/s12944-026-0… Press release: prweb.com/releases/a-10-gene… Thank you to the patients who made this research possible ... and to our collaborators at @gotowardhealth, Wake Forest University School of Medicine, and INCMNSZ.

Post attachment
LipidoSEEN avatar
⟳ Atherosclerosis retweeted
LipidoSEEN@LipidoSeen·Aug 25

La expresión TRAF5 identifica fenotipo de placa estable y menos inflamatorio, y predice independientemente reducción del riesgo cardiovascular tras endarterectomía carotídea Biomarcador potencial para estratificación personalizada del riesgo @ATHjournal tinyurl.com/Traf5plaque

Post attachment